Completion of Capital Reduction in Receivership, Correction of Fractional Share Cancellation, and Reflecting Capital Increase


  • Capital reduction completed: common shares reduced from 363,291,061 to 60,531,114 (83.33% reduction; par value 100 won; capital reduced from 36,329,106,100 won to 6,053,111,400 won)
  • 17,396 fractional shares cancelled with court approval (corrected from previously disclosed 17,291)
  • Post-reduction capital increase via third-party allotment: current total shares 225,531,114, capital 22,553,111,400 won
  • Receivership timeline: commencement 2025-09-16, rehabilitation plan approval and reduction record date 2026-03-20, reduction completion 2026-04-16
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: [Correction of Description] Capital Reduction Completed
  • Company: Eone Diagnomics Genome Center (245620)
  • Submission: Eone Diagnomics Genome Center Co., Ltd.
  • Receipt: 05-11-2026
  • Under KRX KOSDAQ Market Division